We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report.
- Authors
YUE FENG WANG; XIANHONG XIANG; XIAOJUAN PEI; SHUHUA LI; CUILAN TANG; LIANTANG WANG; ZUN-FU KE
- Abstract
Lung cancer is the leading cause of mortality among malignant diseases in humans worldwide. During the last decade, molecular targeted therapies for non-small cell lung cancer using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including gefitinib, have been shown to be a promising approach for patients harboring activating mutations in EGFR. The current study reports a 77-year-old patient diagnosed with adenocarcinoma harboring L858R and T790M point mutations in the EGFR gene. The patient was treated with gefitinib as the second-line therapy, but no clinical benefit was observed. As the majority of patients with lung cancer receiving EGFR-TKI therapy acquire resistance, repeated biopsies and detection of the EGFR mutation state are beneficial for selecting appropriate treatments.
- Subjects
LUNG cancer diagnosis; LUNG cancer treatment; CANCER-related mortality; EPIDERMAL growth factor receptors; GENETIC mutation; GEFITINIB; THERAPEUTICS
- Publication
Oncology Letters, 2014, Vol 8, Issue 3, p1039
- ISSN
1792-1074
- Publication type
Case Study
- DOI
10.3892/ol.2014.2321